Evidence map›Paper›PMID 42558447›Full record

ReviewFrontiers in oncology2026

Modeling rare melanoma subtypes: mechanisms, microenvironments and translational opportunities.

Qingxue Meng, Fengxu Yan, Chenchen You, Ruzhong Xu, Taixing Jing, Danyang Ni, Chenyang Hou, Dandan Xu, Shan Liu, Fei Guo and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qingxue Meng *Hebei Key Laboratory of Systems Biology and Gene Regulation, Technology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Fengxu Yan *Hebei Key Laboratory of Systems Biology and Gene Regulation, Graduate School of Hebei North University, Zhangjiakou, Hebei, China.
Chenchen You *Hebei Key Laboratory of Systems Biology and Gene Regulation, Graduate School of Hebei North University, Zhangjiakou, Hebei, China.
Ruzhong XuHebei Key Laboratory of Systems Biology and Gene Regulation, Graduate School of Hebei North University, Zhangjiakou, Hebei, China.
Taixing JingHebei Key Laboratory of Systems Biology and Gene Regulation, Graduate School of Hebei North University, Zhangjiakou, Hebei, China.
Danyang NiHebei Key Laboratory of Systems Biology and Gene Regulation, Graduate School of Hebei North University, Zhangjiakou, Hebei, China.
Chenyang HouHebei Key Laboratory of Systems Biology and Gene Regulation, Graduate School of Hebei North University, Zhangjiakou, Hebei, China.
Dandan XuHebei Key Laboratory of Systems Biology and Gene Regulation, Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Shan LiuInstitute of Bio-Architecture and Bio-Interactions (IBABI), Shenzhen Medical Academy of Research and Translation (SMART), Shenzhen, China.
Fei GuoHebei Key Laboratory of Systems Biology and Gene Regulation, Department of Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Zhongwu LiDepartment of Pathology, Peking University Cancer Hospital, Beijing, China.
Rensen RanSchool of Basic Medical Sciences, Hainan Medical University, Haikou, Hainan, China.
Weizheng LiangHebei Key Laboratory of Systems Biology and Gene Regulation, Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare melanoma subtypes, such as uveal melanoma, desmoplastic melanoma, mucosal melanoma, and acral melanoma, account for about 10% of all melanomas and exhibit unique genetic backgrounds and immune microenvironments, leading to poor clinical prognosis. Due to their low incidence and limited clinical samples, research and therapeutic strategies for these subtypes remain challenging. This review summarizes the current animal models used for rare melanoma, including spontaneous models, inducible models, genetically engineered models, and xenograft models. Each model has its unique advantages, but also has its own limitations in terms of genetic accuracy, microenvironment simulation, or applicability to immunotherapy research. Future advancements in technology should enhance multi-dimensional simulations of both genetics and the microenvironment, thus promoting mechanistic research and the development of precision therapeutic strategies for rare melanoma.

Indexed as

animal modelsgenetic accuracyimmunotherapymicroenvironment simulationrare melanoma subtypes

Identifiers

PMID42558447
PMCPMC13437512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.